Clinical and Immunological Effects of a Reduced Daily Dose of Stavudine among Antiretroviral Naïve HIV-infected Individuals in Dar es Salaam, Tanzania: A Randomized, Controlled Study

Article Information

Aritcle Type: Research Article

Citation: Buma D, Bakari M, Fawzi W, Mugusi F (2015) Clinical and Immunological effects of a Reduced Daily Dose of Stavudine among Antiretroviral Naïve HIV-infected Individuals in Dar es Salaam, Tanzania: A Randomized, Controlled Study. J HIV AIDS 1 (1): doi http://dx.doi.org/10.16966/jha.103

Copyright: © 2015 Buma D et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Publication history: 

 Received date: 09 April 2015

 Accepted date: 28 May 2015

 Published date: 02 June 2015

Authors :
 Deus Buma^1*      Muhammad Bakar²      Wafaie Fawzi³      Ferdinand Mugusi^2 
1Department of Pharmacy, Muhimbili National Hospital (MNH), Dar es Salaam, Tanzania²Departments of Internal Medicine, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania³Department of Global Health and Population, Harvard School of Public Health, Boston, USA
*Corresponding author: Deus Buma, Muhimbili National Hospital, P.O BOX 65000, Dar es Salaam, Tanzania, Tel: +255787 228282; E-mail: deus.buma@mnh.or.tz, buma70@yahoo.co.uk

Abstract

Objectives: To compare the immunological and clinical effects of a further reduction of stavudine dose to 30 mg once-daily with that of a standard zidovudine containing antiretroviral therapy (ART) regimen in a prospective, open-label randomized controlled study.

Methods: Naïve HIV infected patients were equally randomized to receive either stavudine 30 mg once-daily or a standard dose zidovudine containing regimen. CD4+ T-cell counts, Haemoglobin (Hb), alanine aminotransferase (ALT), Body Mass Index (BMI), WHO stage and patients’ morbidity at baseline, three and six months were determined. Changes between baseline and three as well as six months follow-up were compared within-and between-groups.

Results: Five hundred and twenty patients aged ≥ 18 years were included. Males were 159 (30.6%), with the mean (SD) age of 39 (9) years. Within group comparison indicated that there were statistically significant increases in mean CD4+ cell counts, BMI, and Hb (p<0.0001) at 3 and 6 months from the values at baseline in both groups, but there were not significantly different between groups. Furthermore, there was no statistically significant difference between groups in terms of occurrence of opportunistic infections (OIs) however, there was significant decrease of OIs for subsequent follow up time points compared to baseline status. The overall median adherence rate was 94% (IQR 94%, 98%) in both groups, but patients in the stavudine group had better adherence compared to those in the zidovudine group, p<0.0001. Additionally, liver damage at 6 months, as indicated by elevated ALT, was more likely with the zidovudine based regimen, p <0.0001. There was no statistically significant difference in ALT elevations between the groups at 3 months.

Conclusion: The immunological and clinical outcomes following a regimen employing a reduced dose of stavudine to 30 mg once-daily were similar to those of a standard zidovudine-based antiretroviral regimen.

Keywords

Stavudine; Zidovudine; CD4+cell counts; Adherence



Figure 2:Change in the number of Opportunistic Infections over time


Figure 1:Study Patients Flow
Read Full Article : Here
Published by : Sci Forschen Inc.